camostat has been researched along with molnupiravir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Ledford, H | 1 |
| Aittokallio, T; Biering, SB; Gale, M; Herring, S; Hoffmann, M; Hsiang, TY; Ianevski, A; Pöhlmann, S; Polyak, SJ; Schiffer, JT; Wagoner, J; White, JM; Xu, S | 1 |
1 review(s) available for camostat and molnupiravir
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
2 other study(ies) available for camostat and molnupiravir
| Article | Year |
|---|---|
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication | 2022 |
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Combinations; Humans; Protease Inhibitors; Pyrimidines; SARS-CoV-2 | 2022 |